B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA)

REACTOME PATHWAY
Reactome: R-HSA-56190671 genes2 compounds

The Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) pathway (Reactome ID: R-HSA-5619067) involves 1 genes and is affected by 2 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

SLC1A1

Compounds Affecting Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA)

#CompoundTargets HitStudies
1Glutamic Acid297
2Glutamic Acid300

About the Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) Pathway

The Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) pathway is catalogued in Reactome (ID: R-HSA-5619067) and involves 1 genes. In the BiohacksAI corpus, 2 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include SLC1A1.